Many patients interested in GLP-1 medications also have insulin resistance, prediabetes, or type 2 diabetes
The panel noted that while the primary GLP-1 litigation (MDL 3094) moves forward with stomach-paralysis claims, the scientific mechanisms, unique medical terminology, and specific warning labels required for blindness claims warranted an independent, dedicated management track
As SFN and its metabolites are cleared by the kidney [144], safety and efficacy should first be established in patients with kidney disease, particularly in those with more advanced stages of CKD
Clinical observations from semaglutide trials show that weight loss itself contributes to temperature changes independent of the medication
To understand type 2 diabetes, you need to know what insulin is and why your body needs it